Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity

Journal of Virology

Volumn 72, Issue 5, 1998, Pages 3512-3519

  Parren, Paul W H I ^a   Mondor, Isabelle ^b   Naniche, Denise ^a   Ditzel, Henrik J ^a   Klasse, P J ^c   Burton, Dennis R ^a   Sattentau, Quentin J ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN F(AB) FRAGMENT; NEUTRALIZING ANTIBODY;

ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRION; VIRUS NEUTRALIZATION;

EID: 0031969423     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.5.3512-3519.1998     Document Type: Article

References (58)

1. Armstrong, S. J., T. L. McInerney, L. McLain, B. Wahren, J. Hinkula, M. Levi, and N. J. Dimmock. 1996. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J. Gen. Virol. 77:2931-2941.
2. Bachmann, M. F., U. Kalinke, A. Althage, G. Freer, C. Burkhart, H.-P. Roost, M. Aguet, H. Hengartner, and R. M. Zinkernagel. 1997. The role of antibody concentration and avidity in antiviral protection. Science 276:2024-2027.
3. Barbas, C. F., T. A. Collet, W. Amberg, P. Roben, J. M. Binley, D. Hoekstra, D. Cababa, T. M. Jones, R. A. Williamson, G. R. Pilkington, N. L. Haigwood, E. Cabezas, A. C. Satterthwait, I. Sanz, and D. R. Burton. 1993. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J. Mol. Biol. 230:812-823.
4. Barbas, C. F., III, D. Hu, N. Dunlop, L. Sawyer, D. Cababa, R. M. Hendry, P. L. Nara, and D. R. Burton. 1994. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc. Natl. Acad. Sci. USA 91:3809-3813.
5. Bou-Habib, D. C., G. Roderiquez, T. Oravecz, P. W. Berman, P. Lusso, and M. A. Norcross. 1994. Cryptic nature of envelope V3 region epitopes protects primary human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:6006-6013.
6. Buchacher, A., R. Predl, K. Strutzenberger, W. Steinfellner, A. Trkola, M. Purtscher, G. Gruber, C. Tauer, F. Steindl, A. Jungbauder, and H. Katinger. 1994. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10:359-369.
7. Burton, D. Unpublished results.
8. Burton, D. R., C. F. Barbas, M. A. Persson, S. Koenig, R. M. Chanock, and R. A. Lerner. 1991. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88:10134-10137.
9. Burton, D. R., and D. C. Montefiori. 1997. The antibody response in HIV-1 infection. AIDS 11(Suppl. A):S87-S98.
10. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. H. I. Parren, L. S. W. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, M. Lamacchia, E. Garratty, E. R. Stiehm, Y. J. Bryson, Y. Cao, J. P. Moore, D. D. Ho, and C. F. Barbas. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
11. Clavel, F., and P. Charneau. 1994. Fusion from without directed by human immunodeficiency virus particles. J. Virol. 68:1179-1185.
12. Conley, A. J., M. K. Gorny, J. A. Kessler II, L. J. Boots, M. Ossorio-Castro, S. Koenig, D. W. Lineberger, E. A. Emini, C. Williams, and S. Zolla-Pazner. 1994. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody 447-52D. J. Virol. 68:6994-7000.
13. Della-Porte, A. J., and E. G. Westaway. 1977. A multi-hit model for the neutralization of animal viruses. J. Gen. Virol. 38:1-19.
14. Dimmock, N. J. 1993. Neutralization of animal viruses. Curr. Top. Microbiol. Immunol. 183:1-149.
15. Dimmock, N. J. 1995. Update on the neutralization of animal viruses. Rev. Med. Virol. 5:165-179.
16. Ditzel, H. J., P. W. H. I. Parren, J. M. Binley, J. Sodroski, J. P. Moore, C. F. Barbas, and D. R. Burton. 1997. Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries. J. Mol. Biol. 267:684-695.
17. Fonts, T. R., J. M. Binley, A. Trkola, J. E. Robinson, and J. P. Moore. 1997. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71: 2779-2785.
18. Gauduin, M. C., J. T. Safrit, R. Weir, M. S. Fung, and R. A. Koup. 1995. Pre- and post-exposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. J. Infect. Dis. 171:1203-1209.
19. Gauduin, M.-C., P. W. H. I. Parren, R. Weir, C. F. Barbas, D. R. Burton, and R. A. Koup. 1997. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 3:1389-1393.
20. Gelderblom, H., and Q. Sattentau. Unpublished results.
21. Gorny, M. K., A. J. Conley, S. Karwowska, A. Buchbinder, J.-Y. Xu, E. A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
22. Klasse, P. J., and J. P. Moore. 1996. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell-line-adapted strains of human immunodeficiency virus type 1. J. Virol. 70:3668-3677.
23. Laal, S., S. Burda, M. K. Gorny, S. Karwowska, A. Buchbinder, and S. Zolla-Pazner. 1994. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J. Virol. 68: 4001-4008.
24. McInerney, T. L., L. McLain, S. J. Armstrong, and N. J. Dimmock. 1997. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a post-fusion event. Virology 233:313-326.
25. McKeating, J. A., J. Cordell, C. J. Dean, and P. Balfe. 1992. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type 1 gp120. Virology 191:732-742.
26. McLain, L., and N. J. Dimmock. 1994. Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J. Gen. Virol. 75:1457-1460.
27. Mondor, I., and Q. J. Sattentau. Unpublished results.
28. Montefiori, D. C., B. S. Graham, J. Zhou, D. H. Schwartz, L. A. Cavacini, M. R. Posner, and NIH-NIAID AIDS Vaccine Clinical Trials Network. 1993. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. J. Clin. Invest. 92:840-847.
29. Moore, J. P., Y. Cao, L. Qing, Q. J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C. F. Barbas, D. R. Burton, and D. D. Ho. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:101-109.
30. Moore, J. P., and D. D. Ho. 1995. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9(Suppl. A):S117-S136.
31. Moore, J. P., and J. Sodroski. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
32. Moore, J. P., A. Trkola, B. Korber, L. J. Boots, J. A. Kessler II, F. E. McCutchan, J. Mascola, D. D. Ho, J. Robinson, and A. J. Conley. 1995. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J. Virol. 69:122-130.
33. Muster, T., R. Guinea, A. Trkola, M. Purtscher, A. Klima, F. Steindl, and P. Palese. 1994. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDK-WAS. J. Virol. 68:4031-4034.
34. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Rüker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
35. Nara, P. L., R. R. Garrity, and J. Goudsmit. 1991 Neutralization of HIV-1: a paradox of humoral proportions. FASEB J. 5:2437-2455.
36. Parren, P. W. H. I., and D. R. Burton. 1997. Antibodies against HIV-1 from phage display libraries: mapping of an immune response and progress towards anti-viral immunotherapy. Chem. Immunol. 65:18-56.
37. Parren, P. W. H. I., H. J. Ditzel, R. J. Gulizia, J. M. Binley, C. F. Barbas, D. R. Burton, and D. E. Mosier. 1995. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 9:F1-F6.
38. Parren, P. W. H. I., M.-C. Gauduin, R. A. Koup, P. Poignard, Q. J. Sattentau, P. Fisicaro, and D. R. Burton. 1997. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol. Lett. 58:125-132.
39. Poignard, P., T. Fouts, D. Naniche, J. P. Moore, and Q. J. Sattentau. 1996. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. J. Exp. Med. 183:473-484.
40. Poignard, P., P.-J. Klasse, and Q. J. Sattentau. 1996. Antibody neutralization of HIV-1. Immunol. Today 17:239-246.
41. Potts, B. J., K. G. Field, Y. Wu, M. Posner, L. Cavacini, and M. White-Scharf. 1993. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies. Virology 197:415-419.
42. Roben, P., J. P. Moore, M. Thali, J. Sodroski, C. F. Barbas, and D. R. Burton. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68:4821-4828.
43. Safrit, J. T., M. S. C. Fung, C. A. Andrews, D. G. Braun, W. N. C. Sun, T. W. Chang, and R. A. Koup. 1993. Hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. AIDS 7:15-21.
44. Sattentau, Q. J. 1994. HIV-1 neutralization: antibody-gp120 interactions, p. 135-139. In M. Girard and B. Dodet (ed.), Retroviruses of human AIDS and related animal diseases. Fondation Marcel Merieux, Lyon, France.
45. Sattenlau, Q. J., and J. P. Moore. 1995. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185-196.
46. Sattentau, Q. J. 1996. Neutralization of HIV-1 by antibody. Curr. Opin. Immunol. 8:540-545.
47. Seligman, S. J., J. M. Binley, M. K. Gorny, D. R. Burton, S. Zolla-Pazner, and K. A. Sokolowski. 1996. Characterization by serial deletion competition ELISAs of HIV-1 V3 loop epitopes recognized by monoclonal antibodies. Mol. Immunol. 33:737-745.
48. Shotton, C., C. Arnold, Q. Sattentau, J. Sodroski, and J. A. McKeating. 1995. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 69:222-230.
49. Stamatatos, L., S. Zolla-Pazner, M. K. Gorny, and C. Cheng-Mayer. 1997. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells. Virology 229:360-369.
50. Thali, M., J. P. Moore, C. Furman, M. Charles, D. D. Ho, J. Robinson, and J. Sodroski. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988.
51. Tilley, S. A., W. J. Honnen, M. E. Racho, T. C. Chou, and A. Pinter. 1992. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4 binding site of gp120. AIDS Res. Hum. Retroviruses 8:461-467.
52. Trkola, A., T. Dragic, J. Arthos, J. M. Binley, W. C. Olson, G. P. Allaway, C. Cheng-Mayer, J. Robinson, P. J. Maddon, and J. P. Moore. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-187.
53. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70: 1100-1108.
54. + target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J. Exp. Med. 186:1287-1298.
55. VanCott, T. C., F. R. Bethke, V. R. Polonis, M. K. Gorny, S. Zolla-Pazner, R. R. Refield, and D. L. Birx. 1994. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J. Immunol. 153:449-459.
56. Vijh-Warrier, S., A. Pinter, W. J. Honnen, and S. A. Tilley. 1996. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J. Virol. 70:4466-4473.
57. Wu, L., N. Gerard, R. Wyatt, H. Choe, C. Parolin, N. Ruffing, A. Borsetti, A. Cordoso, E. Desjardin, W. Newman, C. Gerard, and J. Sodroski. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384:179-183.
58. Wyatt, R., J. Moore, M. Accola, E. Desjardin, J. Robinson, and J. Sodroski. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.